StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Free Report) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the stock.
Trinity Biotech Trading Down 7.2 %
Shares of Trinity Biotech stock opened at $0.80 on Thursday. The firm has a fifty day simple moving average of $0.90 and a 200-day simple moving average of $1.54. The stock has a market capitalization of $14.44 million, a price-to-earnings ratio of -0.35 and a beta of 1.03. Trinity Biotech has a 1-year low of $0.74 and a 1-year high of $3.55.
Institutional Investors Weigh In On Trinity Biotech
A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its holdings in shares of Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 5.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent reporting period. 78.97% of the stock is owned by institutional investors and hedge funds.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Recommended Stories
- Five stocks we like better than Trinity Biotech
- Stock Analyst Ratings and Canadian Analyst Ratings
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- Business Services Stocks Investing
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
